Core Viewpoint - Fuan Pharmaceutical (300194) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Qingyutang Pharmaceutical Co., Ltd., has received the GMP compliance certificate from the Philippines' Department of Health Food and Drug Administration [1] Group 1 - The GMP compliance certificate signifies that the subsidiary meets the Good Manufacturing Practice standards required for pharmaceutical production [1]

Core Insights - As of October 31, the number of shareholders for Fu'an Pharmaceutical reached 39,204 [2] Company Summary - Fu'an Pharmaceutical responded to investor inquiries on November 5 regarding its shareholder count [2]

Core Insights - Fu'an Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Qingyutang Pharmaceutical Co., Ltd., has received a GMP compliance certificate from the Philippines' Department of Health, indicating that its production quality management system meets local GMP requirements, which will positively impact the subsidiary's overseas market expansion [1] Group 1 - The GMP compliance certificate was issued for the production of small-volume injectables, including powder and water injections, as well as penicillin-based powder injections [2] - The certificate is valid until July 24, 2028, confirming that the facilities and operations comply with the current drug production quality management standards [2] - The certification process involved a thorough on-site inspection, affirming that the production, sterilization, packaging, labeling, and quality control processes meet the necessary regulatory standards [2]

Core Viewpoint - Fuan Pharmaceutical's subsidiary, Qingyutang Pharmaceutical, has received a GMP compliance certificate from the Philippines' Department of Health, indicating adherence to good manufacturing practices [1] Group 1 - Fuan Pharmaceutical's subsidiary, Qingyutang Pharmaceutical, is fully owned by the company [1] - The GMP compliance certificate is a significant regulatory achievement for the company, enhancing its credibility in the pharmaceutical industry [1] - This certification may open up new market opportunities for Qingyutang Pharmaceutical in the Philippines [1]

Core Viewpoint - Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Qingyutang Pharmaceutical Co., Ltd., has received a GMP compliance certificate from the Philippines' Food and Drug Administration [1] Group 1 - The GMP compliance certificate signifies that Qingyutang meets the necessary standards for good manufacturing practices, which is crucial for pharmaceutical companies operating in international markets [1] - This certification may enhance the company's credibility and facilitate its expansion into the Southeast Asian market [1]

Core Viewpoint - Fuan Pharmaceutical's subsidiary, Qingyutang Pharmaceutical, has received a GMP compliance certificate from the Philippines' Department of Health, indicating its adherence to good manufacturing practices [1] Group 1 - Fuan Pharmaceutical's subsidiary, Qingyutang Pharmaceutical, is recognized for its compliance with GMP standards [1] - The GMP compliance certificate is a significant regulatory achievement that may enhance the company's market presence in the Philippines [1]

Core Viewpoint - The announcement indicates that the wholly-owned subsidiary of Fu'an Pharmaceutical, Qingyutang, has received the GMP compliance certificate from the Philippines' Department of Health, which will positively impact the company's overseas market expansion [1] Group 1: Certification Details - Qingyutang has passed the GMP compliance inspection at two production sites located in Chongqing's Changshou District and Yubei District [1] - The validity of the GMP compliance certificate is until July 24, 2028, for one site and until July 18, 2028, for the other site [1] Group 2: Market Implications - The successful GMP compliance indicates that Qingyutang's quality management system for formulation production meets the Philippines' GMP requirements [1] - This certification is expected to facilitate the company's related products' expansion into overseas markets [1]

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假 记载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）全资子公司福安药业集 团庆余堂制药有限公司（以下简称"庆余堂"）于近日收到菲律宾共和国卫生部 食品药品监督管理局签发的《GMP 符合性证书》，现将具体情况公告如下： | 证书编号 | 企业名称 | 地址 | 认证范围 | 有效期至 | 检查结论 | | --- | --- | --- | --- | --- | --- | | | | 重 庆 市 长 寿 | 剂型：小容量注射剂（粉针剂） | | 菲律宾食品药品监督管理 | | CDRR-CGM | | 区化南一路 1 | 车间：青霉素类粉针剂车间（W22） | 2028.07.24 | 局通过现场检查认证了企 | | P-FA-209-01 | | 号 | 场地生产操作：生产、灭菌、包装、贴标及质 | | 业符合现行《药品生产质 | | | | | 控检测 | | 量管理规范》（GMP）要求， | | | | | 剂型：小容量注射剂（水针剂、头孢粉针剂）； | | 符合政令号 | | | 庆余堂 | | 吸入溶 ...

Core Viewpoint - 福安药业 is a company engaged in the research, production, and sales of antibiotic raw materials and formulations, with a unique qualification in controlled substances and certain technical barriers [1] Group 1: Business Performance - In Q3 2025, 福安药业 reported revenue of 1.315 billion yuan, ranking 43rd among 110 peers, with the industry leader, 华东医药, generating 32.664 billion yuan [2] - The net profit for the same period was 166 million yuan, placing the company 38th in the industry, while the top performer, 恒瑞医药, achieved a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - 福安药业's debt-to-asset ratio was 25.36% in Q3 2025, down from 27.09% year-on-year and below the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for the same period was 36.68%, a decline from 52.96% year-on-year and lower than the industry average of 57.17% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.44% to 39,000, while the average number of circulating A-shares held per shareholder increased by 0.44% to 24,800 [5] - The top ten circulating shareholders included 香港中央结算有限公司, which held 4.9804 million shares, a decrease of 470,000 shares from the previous period [5] Group 4: Management Compensation - The chairman, 汪天祥, received a salary of 920,100 yuan in 2024, a slight increase from 919,800 yuan in 2023 [4] - The general manager, 汪璐, earned 776,400 yuan in 2024, up from 776,200 yuan in 2023 [4] Group 5: Future Outlook - 福安药业's H1 2025 report indicated a total revenue of 921 million yuan, a year-on-year decrease of 35.76%, and a net profit of 113 million yuan, down 47.74% [5] - The company plans to enhance market development for non-collective procurement products and accelerate new drug research, with 39 drug projects currently in the registration process, six of which have been approved for production [5]

证券代码：300194 证券简称：福安药业 公告编号：2025-040 福安药业（集团）股份有限公司 关于子公司参与全国药品集中采购拟中选的公告 2025 年 10 月 27 日，福安药业（集团）股份有限公司（以下简称"公司"） 全资子公司福安药业集团庆余堂制药有限公司、福安药业集团宁波天衡制药有限 公司、福安药业集团烟台只楚药业有限公司、福安药业集团湖北人民制药有限公 司、重庆生物制品有限公司（以下分别简称"庆余堂、天衡制药、只楚药业、人 民制药、重庆生物"）参与了国家组织药品集中采购和使用联合采购办公室（以 下简称"联合采购办公室"）组织的第十一批全国药品集中采购的投标工作。经 联合采购办公室开标、评标后，公司全资子公司部分药品拟中选本次集中采购， 现将相关情况公告如下： 一、拟中选产品情况 | 拟中选 | 拟中选药品名 | | | 年 2024 度销售 收入（万 | 占 2024 年度主 营业务 | | --- | --- | --- | --- | --- | --- | | 企业 | 称 | 注册分类 | 适应症 | 元） | 收入的 比例 | | | | | | | （%） | | | 注射用头孢 ...